Addrenex is also continuing to enroll patients in an additional Phase III trial using Clonicel in combination with stimulants such as methylphenidate and dextro-amphetamine/amphetamine to treat attention deficit and hyperactivity disorder (ADHD).
In July 2007, Sciele signed an exclusive licensing agreement with Addrenex to market a sustained-release formulation of clonidine hydrochloride for the treatment of ADHD and hypertension.
Moise Khayrallah, CEO of Addrenex, said: “Our goal is to provide another option for patients who need an alternative to stimulants or who may benefit from combination therapy using Clonicel together with other approved ADHD medications.”